Wow so many 'notifications' that I thought would be separate announcements have been listed under "Recent Operational Highlights" ... all good ones I might add
... Phase II DEP Docetaxel Trials started in multiple locations is a big plus, especially as they are saying 'no neutropenia' from all the patients dosed in the Phase II so far..... therefore replicating Phase I indications.
I also like their comment about how FDA refunded our $3.2m application fee ... IMO that shows FDA are supporting this application as much as they can, so again IMO approval is just a formality.
Plenty of cash at bank and other trials in the pipeline ... all looks good to me folks !
GLTA
